Novel PDE4 Inhibitor Slows IPF Progression

By News Health
6 hours Ago

(MedPage Today) — Novel oral agent nerandomilast slowed progression of idiopathic pulmonary fibrosis (IPF), even atop background antifibrotic therapy, the phase III FIBRONEER-IPF trial showed.
Forced vital capacity (FVC) declined from baseline…

Source link : https://www.medpagetoday.com/meetingcoverage/ats/115633

Author :

Publish date : 2025-05-18 21:15:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

GPs to help NHS find more infected blood victims

Palopegteriparatide Benefits Sustained in Adults With Chronic Hypoparathyroidism

LARC Counseling Vital for Adolescent Mothers at Risk for a Short-Interval Pregnancy

Biden Diagnosed With Aggressive Cancer

'The Next World War Will Be a Biowar': What We Heard This Week

Adding CT, Symptoms Improves COPD Diagnosis